---
layout: default
title: Venetoclax
parent: 僅模型預測 (L5)
nav_order: 381
evidence_level: L5
indication_count: 10
---

# Venetoclax
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using no additional skill — this is a direct data-to-report transformation task per the fixed template; brainstorming/systematic-debugging don't apply here.

# Venetoclax: From Chronic Lymphocytic Leukemia to Pregerminal Center CLL/SLL

## One-Sentence Summary

Venetoclax is a selective, orally available BCL-2 inhibitor whose established use in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) is documented within the supporting literature of this evidence pack. The TxGNN model predicts a signal for **pregerminal center CLL/SLL** — an IGHV-unmutated, poor-prognosis molecular subtype of CLL/SLL — but this specific subgroup currently has **0 dedicated clinical trials** and only **1 supporting publication**, marking it as an early, hypothesis-generating signal rather than a validated new indication.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Chronic Lymphocytic Leukemia (CLL) — per embedded literature evidence (e.g., PMID 28724540, 33230098) |
| Predicted New Indication | Pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L4 |
| Norway Market Status | ✗ Not Marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Research Question |

## Why is This Prediction Reasonable?

Venetoclax selectively inhibits BCL-2, a pro-survival protein that is overexpressed in most B-cell malignancies, thereby restoring the intrinsic (mitochondrial) apoptotic pathway and triggering tumor cell death. This mechanism is well documented across the pack's literature evidence (e.g., PMID 28724540: "a highly potent and selective oral BCL-2 antagonist... approved in chronic lymphocytic leukemia"; PMID 33230098: FDA-approved for AML in combination with hypomethylating agents). A formal, structured MOA record from DrugBank was not retrievable for this candidate (data gap DG002, High severity).

The predicted "new" indication is not a distinct disease but a refined molecular subtype *within* CLL/SLL itself — specifically the IGHV-unmutated (U-CLL), pre-germinal-center-origin subgroup, historically associated with poorer prognosis compared to the mutated (M-CLL, post-germinal-center) subtype captured separately at rank 2. Since BCL-2 dependency is a pathogenic hallmark of CLL regardless of IGHV mutation status, the mechanistic rationale for venetoclax activity plausibly extends to this subgroup.

However, the single supporting reference (PMID 35158929, a 2022 review on B-cell receptor structure/function in CLL) only characterizes the biological distinction between U-CLL and M-CLL — it does not report venetoclax outcomes stratified by this subtype. No dedicated clinical trial isolates this molecular subgroup, so the prediction should be read as a biologically plausible refinement of venetoclax's already-established CLL indication, not as independent proof of efficacy in a new disease.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [35158929](https://pubmed.ncbi.nlm.nih.gov/35158929/) | 2022 | Review | Cancers | Characterizes the pre-germinal center (U-IGHV, poor prognosis) vs. post-germinal center (M-IGHV, good prognosis) CLL subsets and their B-cell receptor structure/function differences; does not report venetoclax-specific outcomes. |

## Norway Market Information

No marketing authorization records are available for Venetoclax in this evidence pack — the drug is currently not marketed (0 licenses on file).

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (selective BCL-2 inhibitor; not a conventional cytotoxic chemotherapeutic) |
| Myelosuppression Risk | High — literature within this pack reports thrombocytopenia in up to 80% of patients in combination regimens (PMID 38264906) and identifies tumor lysis syndrome and myelosuppression as the most common toxicities of venetoclax-based therapy (PMID 35659041) |
| Emetogenicity Classification | Low to Moderate (consistent with the oral targeted BCL-2 inhibitor class; not separately quantified in this evidence pack) |
| Monitoring Items | CBC with differential (neutropenia/thrombocytopenia), tumor lysis syndrome labs during dose ramp-up (potassium, uric acid, calcium, phosphate, creatinine), liver function |
| Handling Protection | Standard hazardous/antineoplastic drug handling precautions recommended for pharmacy compounding and dispensing, consistent with its classification as an antineoplastic agent |

## Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not retrievable in this evidence pack (TFDA label retrieval flagged as a Blocking data gap, DG001).

## Conclusion and Next Steps

**Decision: Research Question**

**Rationale:**
The BCL-2-dependency mechanism underlying venetoclax's established CLL activity is biologically plausible for this IGHV-unmutated subtype, but the complete absence of dedicated clinical trials and reliance on a single non-specific review article means the evidence does not yet support progression beyond a research hypothesis. (For context, other predicted indications in this pack — e.g., myeloid leukemia, evidence level L1 — already have Phase 3-supported, guideline-aligned venetoclax regimens and may warrant separate, higher-priority review.)

**To proceed, the following is needed:**
- TFDA/regulatory label data (warnings, contraindications) — currently a Blocking gap
- Structured mechanism-of-action documentation from DrugBank
- A clinical trial or retrospective cohort stratifying venetoclax outcomes specifically by IGHV mutation status in CLL/SLL
- Safety monitoring plan addressing myelosuppression and tumor lysis syndrome risk
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

